Strategic acquisition ISTA operated as a leading branded eye care business and was acquired by Bausch + Lomb, which later became part of Valeant. This history indicates a pathway for reinvigorated ophthalmic portfolios and potential collaboration on legacy products or new formulations within the Bausch + Lomb/ Valeant ecosystem.

Product portfolio Key products span inflammation and pain management, allergic conjunctivitis, glaucoma and ocular care agents. This broad ophthalmic footprint suggests cross-sell opportunities to expand into adjacent eye care segments with existing sales force and distribution channels.

Sales force leverage Original U.S. sales force exceeded 165 representatives targeting ophthalmologists, optometrists and allergists. A combined, well-established field team offers a channel to accelerate new product launches, educate clinicians, and drive pull-through for pipeline products.

Financial potential With revenue in the broad range of hundreds of millions and ongoing corporate consolidation, there is a potential to position new ophthalmic therapies within a larger, financially robust platform, enabling scale-up of marketing investments and partnerships.

Technology & partnerships Adoption of a modern tech stack (including analytics and CRM tools) and recent industry partnerships indicate a favorable environment for data-driven sales initiatives, digital outreach, and co-development or co-marketing opportunities with allied pharma and biotech entities.